Abstract: The present invention is in the field of antiperspirant compositions, in particular, compositions comprising antiperspirant actives. Disclosed is an anhydrous antiperspirant composition comprising an inorganic polyionic cluster having structure of (I) or (II); where M is Ca or Mg; and wherein the composition is substantially free of abrasives, which means less than 3.0% by weight of the composition; wherein anhydrous means the water content of the composition is less than 3.0%.

Abstract: The present disclosure discloses a method of preparing a carbon-coated ceria hollow sphere, which includes the following steps of: S110, dispersing silica in a solvent to obtain a silica dispersion; S120, performing a hydrothermal reaction between the silica dispersion and a cerium salt to obtain a ceria-coated silica microsphere; S140, coating the ceria-coated silica microsphere with a carbon source to obtain a primary product, wherein the carbon source is dopamine; S160, sintering the primary product under a protective gas atmosphere to obtain a carbon-coated ceria microsphere; and S170, etching the carbon-coated ceria microsphere by using an etchant to obtain a carbon-coated ceria hollow sphere.

Abstract: The present disclosure discloses a method of preparing a carbon-coated ceria hollow sphere, which includes the following steps of: S110, dispersing silica in a solvent to obtain a silica dispersion; S120, performing a hydrothermal reaction between the silica dispersion and a cerium salt to obtain a ceria-coated silica microsphere; S140, coating the ceria-coated silica microsphere with a carbon source to obtain a primary product, wherein the carbon source is dopamine; S160, sintering the primary product under a protective gas atmosphere to obtain a carbon-coated ceria microsphere; and S170, etching the carbon-coated ceria microsphere by using an etchant to obtain a carbon-coated ceria hollow sphere.

Abstract: An oral care composition is disclosed comprising calcium silicate and high refractive index particles wherein the calcium silicate and high refractive index particles are present in a relative weight ratio of 1110 to 511 and the surfaces of the high refractive index particles are substantially uncoated by calcium.

Abstract: An oral care composition is disclosed comprising calcium silicate and high refractive index particles wherein the calcium silicate and high refractive index particles are present in a relative weight ratio of 1110 to 511 and the surfaces of the high refractive index particles are substantially uncoated by calcium.

Abstract: The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof.

Abstract: The disclosure provides methods, and compositions for use in methods, for expanding lymphocyte populations in vitro, ex vivo, and in vivo using IL-15R?/IL-15 activator complexes.

Abstract: A method for diagnosis or therapeutics of tumor which is characterized by administering an amount of a glycoprotein having a molecule capable of specifically binding to a lectin to a subject in need of such diagnosis or treatment and use of the glycoprotein for the manufacture of a diagnostic and therapeutic agent useful in detection or therapeutics of tumor are disclosed.